AUTEK(SZ:300595)2021-08-04 16:00Supply Chain and Raw Materials - The company reported a stable supply relationship with Bausch & Lomb for raw materials, ensuring supply and price stability during the reporting period[2]. - The company is diversifying its raw material suppliers to mitigate risks associated with supplier concentration[55]. - The company maintains a stable supply relationship with Bausch & Lomb for raw materials, ensuring supply and price stability[54]. Financial Performance - The company's revenue for the reporting period reached ¥570,137,743.19, representing a 91.94% increase compared to ¥297,037,401.77 in the same period last year[13]. - Net profit attributable to shareholders was ¥255,968,022.93, a 100.09% increase from ¥127,923,865.88 year-on-year[13]. - The net cash flow from operating activities was ¥276,162,123.91, showing a significant increase of 154.80% compared to ¥108,383,645.95 in the previous year[13]. - Basic earnings per share increased to ¥0.3018, up 98.55% from ¥0.1520 in the same period last year[13]. - Total assets at the end of the reporting period were ¥2,581,263,412.76, reflecting a 16.64% increase from ¥2,212,923,975.75 at the end of the previous year[13]. - The net assets attributable to shareholders increased to ¥1,911,563,210.47, a rise of 9.11% from ¥1,751,983,461.21 at the end of the previous year[13]. - The company achieved operating revenue of ¥570,137,743.19, representing a year-on-year growth of 91.94% and a growth of 117.21% compared to 2019[17]. - Net profit attributable to shareholders reached ¥255,968,022.93, an increase of 100.09% year-on-year and 119.49% compared to 2019[17]. Research and Development - The company is currently in the pilot testing phase for lens material research projects conducted by its R&D center[2]. - The company has established a comprehensive R&D innovation system, focusing on eye health and myopia prevention[22]. - The company has received one utility model patent and one software copyright during the reporting period[22]. - The R&D center's lens material project has entered the pilot verification stage, indicating progress in product development[55]. - Research and development investment rose by 58.53% to ¥13,284,158.18 from ¥8,379,821.72, reflecting the company's commitment to innovation[35]. Market Competition - The competitive landscape includes 7 imported brands and 1 domestic brand for orthokeratology lenses, indicating intensified competition despite market expansion[3]. - The market for orthokeratology technology is expected to grow due to increasing government attention on myopia prevention[19]. - The company is a leading enterprise in the domestic orthokeratology lens segment, with 15 years of industry experience and a wide user base[23]. Product Development and Innovation - The company plans to enhance product competitiveness through regular innovation, personalized services, and marketing support[3]. - The company emphasizes personalized design and production, ensuring timely delivery and stability for custom orders[23]. - The company's orthokeratology lenses allow for a maximum myopia reduction of 600 degrees, exceeding the typical market limit of 500 degrees[23]. - The company has launched several safety auxiliary products, including disinfection boxes for hard lens trial sets and real-time corneal status monitors[31]. Corporate Governance and Shareholder Relations - The company has established a comprehensive governance structure and improved internal management to enhance operational standards and protect shareholder rights[68]. - The company plans to not distribute cash dividends or issue bonus shares for the first half of 2021[64]. - The company granted 512,000 restricted stocks at a price of 33.78 CNY per share to 25 incentive targets as part of its 2020 restricted stock incentive plan[65]. - The company intends to repurchase and cancel 163,828 restricted stocks from various incentive targets as part of its stock incentive plans[66]. Operational Challenges and Risks - The ongoing pandemic may lead to local government restrictions affecting the operation of optical and vision care services, potentially reducing product orders[3]. - The company is facing risks related to changes in national policies on medical device production and operation, which could impact business plans[54]. - The overall financial health remains a concern, with several subsidiaries reporting significant losses, necessitating a strategic review of operations[130]. Expansion and Market Presence - The company has established over 1200 cooperative terminals by adding more than 100 new partners in the first half of 2021[30]. - The company plans to open 50 new retail locations by the end of 2022, aiming for a 15% increase in foot traffic[128]. - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in sales in that region by the end of 2022[129]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product portfolio[131]. Financial Reporting and Compliance - There were no discrepancies between the financial reports prepared under international accounting standards and those under Chinese accounting standards[14]. - The company has maintained a commitment to transparency in financial reporting, adhering to relevant accounting standards and regulations[138]. - The financial statements were prepared based on the assumption of going concern, with no identified issues affecting the company's ability to continue operations for the next 12 months[138]. User Engagement and Community Initiatives - User data indicates a total of 1.5 million active users, representing a 20% increase year-over-year[129]. - The company invested 1 million RMB to develop a digital monitoring system for myopia prevention, which is provided free of charge to educational institutions and hospitals[69]. - A total of 1,052 public welfare activities were conducted, including role-playing and lectures on myopia prevention[69].